Latest Videos |view all videos
Video
Roswell Park Achieves National Accreditation for Rectal Cancer Care
Team recognized by National Accreditation Program for Rectal Cancer and American College of Surgeons.
Video
Expertise in Rare Tumor Surgery Neurosurgery: What Sets Roswell Park Apart
At Roswell Park Comprehensive Cancer Center, rare tumors of the brain, spinal cord and neurons are treated with uncommon expertise.
Video
Meet the Team: Eleanor Fallon, MD
Eleanor Fallon, MD, joined Roswell Park Comprehensive Cancer Center to combine her two passions: treating melanoma and non-melanoma skin cancers and research into how immunotherapy can be used to make other therapies more effective.
Video
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., is evaluating a new chimeric antigen receptor (CAR) T-cell therapy that could dramatically transform the treatment of relapsed ...
Video
New Trial Tests Gabapentin As Treatment for Mucositis, Replacing Opioids
A new trial available at Roswell Park Comprehensive Cancer Center, organized by the Alliance for Clinical Trials in Oncology Foundation, is looking to determine the efficacy of using gabapentin for pain mitigation.
Video
Roswell Park Offering CAR T Trial for Autoimmune Conditions
While most CAR T-cell therapies and clinical trials are directed at cancers, a new phase 1 trial at Roswell Park Comprehensive Cancer Center is open and recruiting patients with a variety of autoimmune conditions.
Video
Meet the Team: Maksim Liaukovich, MD
Welcome a Maksim Liaukovich, MD, a hematologic oncologist, to Roswell Park.
Video
New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients
While an estimated 95% of “younger” patients diagnosed with Hodgkin lymphoma are still alive and into survivorship within five years of their diagnosis, their long-term health suffers from the aggressive treatment needed to fight the disease.
Video
A new, first-in-humans clinical trial for hepatocellular carcinoma uses an “armored” CAR T-cell therapy designed to resist the hostile tumor microenvironment found in 77% of patients with this disease.
BROADCASTMED